J&J Medical Connect
PREZCOBIX®

(darunavir-cobicistat)

J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

PREZCOBIX® (darunavir-cobicistat)
Medical Information

PREZCOBIX - Open Bottle Stability

Last Updated: 07/17/2026

SUMMARY

  • An in-use stability study of PREZCOBIX 800/150 mg oral film-coated tablets in 120 mL high density polyethylene (HDPE) bottles was performed to simulate the daily use of the medication by the patient.1
  • The product remained stable at 25°C/60% relative humidity (RH) and 30°C/75% RH when stored in an HDPE bottle that was opened once daily for 6 weeks. This study was not conducted to assess open bottle stability for longer periods of time.1

LITERATURE SEARCH

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 25 November 2025.

References

Show
1 Data on File. In-Use Stability Report for 800/150-mg Darunavir/Cobicistat Oral Film-Coated Tablets. Janssen Research & Development, LLC. TV-TEC-147553; 2017.  

Would you like to clear and leave your conversation? Message history will be lost.